Last reviewed · How we verify
NCT07073053
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
Phase 4 trial testing Semaglutide 1.0 mg in Glucagon-Like Peptide-1 Receptor Agonists in 60 participants. Not yet recruiting.
31 July 2028
Quick facts
| Lead sponsor | Taipei Veterans General Hospital, Taiwan |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 October 2025 |
| Primary completion | 31 July 2028 |
| Estimated completion | 31 July 2028 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Semaglutide 1.0 mg — full drug profile →
- Semaglutide 0.5 mg — full drug profile →
Conditions studied
- Glucagon-Like Peptide-1 Receptor Agonists — all drugs for Glucagon-Like Peptide-1 Receptor Agonists →
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Coronary Arterial Disease (CAD) — all drugs for Coronary Arterial Disease (CAD) →
Sponsor
Taipei Veterans General Hospital, Taiwan
Who can join
20 and older, any sex, with Glucagon-Like Peptide-1 Receptor Agonists or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators plan to enroll 60 patients from the outpatient clinics or inpatient wards of the Metabolism and Cardiology departments who, within the past three months, have undergone coronary angiography for the treatment of coronary artery disease, are currently using sodium-glucose cotransporter-2 (SGLT-2) inhibitors for glycemic control, and have not received glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy for more than three months. A randomized controlled clinical trial will be conducted, with 20 participants randomly assigned to receive semaglutide (a GLP-1 RA) at 1 mg once weekly for 6 months, another 20 participants to receive semaglutide at 0.5 mg once weekly for 6 months, and the control group (20 participants) to continue with standard treatment for 6 months. The effects after 6 months will be evaluated in terms of endothelial function, glycemic control indicators including glycemic variability assessed via continuous glucose monitoring (CGM), oxidative stress markers, and the incidence of symptomatic hypoglycemia. According to the treatment guidelines for type 2 diabetes, either GLP-1 receptor agonists or SGLT-2 inhibitors should be prioritized in patients with type 2 diabetes and coronary artery disease. Therefore, the medication choices in both the intervention and control groups in this study align with current treatment guidelines.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07073053
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Semaglutide 1.0 mg
Trials testing the same drug.
- NCT07223983 — Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) · Phase 1 · recruiting
- NCT07251556 — GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis · Phase 4 · not yet recruiting
- NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. · Phase 4 · active not recruiting
- NCT03552757 — Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obes · Phase 3 · completed
- NCT03288740 — A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects · Phase 1 · completed
Other Taipei Veterans General Hospital, Taiwan trials
Trials by the same sponsor.
- NCT07463443 — Effectiveness of Chatbot for Improving Caregiving Outcomes in Primary Caregivers of Geriatric Pneumonia Patients: A Stud · NA · not yet recruiting
- NCT07400757 — Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease · NA · not yet recruiting
- NCT07362134 — Pulsed-Field Ablation for Recurrent Atypical Atrial Flutter · NA · enrolling by invitation
- NCT07473687 — Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room · recruiting
- NCT07344207 — GUARD-PH: Guided Use of AI-ECG for Risk Detection of PH in Surgery (GUARD-PH Trial) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07073053 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Veterans General Hospital, Taiwan
- Last refreshed: 18 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07073053.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing